ZURA
Zura Bio Ltd
NASDAQ · Healthcare · Biotechnology · US
$4.02
+0.75%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -45.7%
- EBIT
- -40.6%
- EPS
- -57.7%
- Free cash flow
- -52.7%
- Operating cash flow
- -52.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +31.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -30.9%
- EBIT
- -36.3%
- Net income
- -31.0%
- EPS
- -76.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026